EN FR
EN FR
Overall Objectives
Bilateral Contracts and Grants with Industry
Bibliography
Overall Objectives
Bilateral Contracts and Grants with Industry
Bibliography


Section: Research Program

Methodologies for large-scale datasets

Until recently, neuroimaging studies were often restricted to series of about 20-30 patients. As a result, such studies had a limited statistical power and could not adequately model the variability of populations. Thanks to wider accessibility of neuroimaging devices and important public and private funding, large-scale studies including several hundreds of patients have emerged in the past years. In the field of Alzheimer’s disease (AD) for instance, one can cite the Alzheimer’s Disease Neuroimaging Initiative (ADNI) including about 800 subjects (patients with AD or mild cognitive impairment (MCI) and healthy controls) or the French cohort MEMENTO including about 2000 subjects with memory complaint. These are most often multicenter studies in which patients are recruited over different centers and images acquired on different scanners. Moreover, cohort studies include a longitudinal component: for each subject, multiple images are acquired at different time points. Finally, such datasets often include multimodal data: neuroimaging, clinical data, cognitive tests and genomics data. These datasets are complex, high-dimensional and often heterogeneous, and thus require the development of new methodologies to be fully exploited.

In this context, our objectives are:

  • to develop methodologies to acquire and standardize multicenter neuroimaging data;

  • to develop imaging biomarkers based on machine learning and longitudinal models;

  • to design multimodal analysis approaches for bridging anatomical models and genomics.

The first two aspects focus on neuroimaging and are tightly linked with the CATI project. The last one builds on our previous expertise in morphometry and machine learning, but aims at opening new research avenues combining imaging and “omics” data. This is developed in strong collaboration with the new biostatistics/bioinformatics platform of the IHU-A-ICM.